European Partnership on One Health Antimicrobial Resistance

Calls

EUP OHAMR JTC 2026 visual. A petri dish combined with a green circle on a blue background.

Joint transnational call 2026

This first EUP OHAMR joint transnational call for projects will explore new treatments to tackle AMR. The call "Treatments and adherence to treatment protocols", involves 37 funding organisations from 28 different countries with an estimated total call budget of over 31 million Euro. The call is co-funded by the European Union.

Call status
Status: Closed call

Closed 2026

Thematic areas
Category: Interventions
Category: Therapeutics
Category: Transmission and evolution
Call details
Call title Treatments and adherence to treatment protocols
Focus area Provide innovative and cost-effective treatment options
Grant form Project grant
Grant period 3 years
Call opens 18 November 2025
Call closes 2 February 2026 (pre-proposals)
Call budget Over 31 million Euros

Please note

  • Only transnational research and innovation projects will be supported.
  • An online partner search tool is available.
  • Applications must be submitted to the EUP OHAMR submission platform and follow the EUP OHAMR pre-proposal/full proposal template.
  • Applications to EUP OHAMR joint transnational calls can require the submission of additional information on national funding platforms.
  • All applicants must have fulfilled both joint and national requirements for an application to be eligible.
  • Applicants are strongly advised to confirm their funding eligibility with their national/regional funding organisation before submission.
  • For updates to the call text, please see the History of change section at the bottom of this page.

1. Aim of the call

Drug-resistant infections are responsible for an increasing number of treatment failures, increased mortality and decreased food productivity. Inappropriate use, poor adherence to prescriptions, and overuse of antibiotics are one of the main drivers of AMR and have a detrimental impact on the effectiveness of these critical medicines.

To develop novel treatment protocols or alternative treatment strategies against infectious diseases and to improve, preserve and reinforce the clinical efficacy of the current treatment antimicrobials is vital. It is also necessary to identify barriers preventing the proper adherence of the end-users to the treatment protocols already in place.

This first EUP OHAMR Call aims to improve the treatment success rates of the patients/animals/plants affected by bacterial or fungal infections by providing new treatment options while reducing the risk of resistance in the different One Health settings.


2. Call topics

Research & innovation proposals submitted under this call must address one of the following topics:

Topic 1

Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.

Resistance limits the usability of many commonly-used antibiotics and antifungal agents in Human Health, Animal Health, and Plant Health.

Proposals addressing this topic should identify and develop therapies to be used in combination (combination of different antimicrobials, or combination of an antimicrobial and a non-antimicrobial that improves activity or facilitates a better targeting towards the site of infection) to reduce the development of resistance against antibacterial and antifungal treatments and extend the usability of inexpensive and readily available antimicrobials. These studies should be underpinned by scientific rationale and mechanism of action of these treatments.

In the framework of this topic, improvement of existing combination treatments is eligible (i.e. pharmacokinetics and pharmacodynamics, mode of administration). The choice of the targeted pathogens should be well justified. For the proposals having a Human Health interest, the proposed combination treatment should be directed against one of the bacterial or fungal pathogens included in the WHO priority lists:

Topic 2

Develop tools and methods to improve adherence to treatment protocols.

A low adherence to the treatment protocols by end-users (patients, farmers, citizens) leads to a decreased probability of success and to an increased risk of resistance to antibacterial and antifungal treatments.

Proposals addressing this topic should identify the reasons of poor adherence to treatment protocols (Human, Animal, Plant), and/or develop innovative tools (including digital tools) and methods (including sociological and behavioural approaches) to improve the adherence to treatment protocols and/or test and compare the efficiency of existing or innovative tools and methods on the adherence to treatment protocols.

Engagement with end-users is mandatory. The consideration of vulnerable groups, which often have reduced access to conventional health and care services, is expected.

Topic 3

Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.

Proposals addressing this topic are expected to assess the impact of mechanisms of action, formulations, routes of administration and treatment regimens of antibacterial and antifungal drugs authorized for veterinary and agricultural use on the risk of emergence and transmission of AMR to humans and the environment.

Proposals addressing this topic should also aim to improve the formulation, dosage, delivery, routes of administration and treatment regimens (including pharmacokinetics and pharmacodynamics) currently used in the veterinary and agricultural sector, to decrease the risk of cross-resistance, or transmission to humans and the environment.

The aim is to generate evidence to support policies that restrict certain antimicrobials for exclusive human use and inform policies such as the WHO List of Medically Important Antimicrobials (who.int).

The following requirements applies for all call topics:

  • Proposals should consider how the proposed approach will impact the risk of resistance in other One Health settings, and how the proposed approach could be extended to other One Health settings.
  • Proposals should explain their feasibility by outlining realistic objectives, practical methodologies, and achievable timelines (e.g.: workplan, risk identification, allocation of resources, capacity of the consortium to conduct the work, business plan if the proposal envisages commercial component, etc).
  • Proposals must clearly demonstrate the potential health, social and/or economic impact(s) of the expected results. In particular, the proposals should explain how the uptake of the expected project results by the society/ end-users/ next actors in the value chain will be facilitated.
  • Proposals should clearly demonstrate the benefit of working together and the unique contribution of each partner (i.e. expertise, resources). In addition, the proposals should demonstrate the added-value of transnational collaboration: sharing of expertise and resources (models, databases…), harmonization of data, access to innovative technologies, etc.
  • Participation of the private sector (start-up, SMEs, industry) in the consortium is encouraged for all call topics if appropriate and if allowed according to national funding eligibility rules.

3. Participating countries and funding organisations

Below is an overview of the participating countries and funding organisations in the EUP OHAMR joint transnational call 2026: Their national/regional funding commitments, expected number of funded proposals, eligible topics and One Health settings, and the eligibility of clinical trials (pilots).

The financial commitments and expected number of funded proposals per funding organisation.

CountryFunding organsiationNational/regional financial commitmentExpected no. of funded proposals
AustriaFonds zur Förderung der Wissenschaftlichen Forschung (FWF)1 400 000 €3-4
BelgiumBelgium Fonds de la Recherche Scientifique (FNRS)300 000 €1
BelgiumFonds Wetenschappelijk Onderzoek-Vlaanderen (FWO)700 000 €2-3
BelgiumService Public de Wallonie (SPW)1 000 000 €1-2
CanadaCanadian Institutes of Health Research (CIHR)600 000 CAD1
Czech RepublicMinisterstvo Zdravotnictvi Ceske Republiky (MZCR)/ Agentura pro zdravotnicky vyzkum (AZVCR)500 000 €2
DenmarkInnovationsfonden, Innovation Fund Denmark (IFD)1 300 000 €2-5
EstoniaSihtasutus Eesti Teadusagentuur (ETAG)300 000 €1
FinlandSuomen Akatemia (AKA)1 000 000 €2-4
FranceAgence Nationale de la Recherche (ANR)2 000 000 €10
GermanyBundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)/ Deutsches Zentrum für Luft- und Raumfahrt Projektträger (DLR-PT)2 500 000 €10
HungaryNemzeti Kutatási, Fejlesztési Innovációs Hivatal (NKFIH)300 000 €1-2
IrelandDepartment of Agriculture, Food and the Marine (DAFM) 600 000 €2-3
IrelandTaighde Éireann – Research Ireland (TÉ-RI)1 000 000 €2-3
IrelandThe Health Research Board (HRB)530 000 €1-2
IsraelMinistry Of Health – Chief Scientist Office (CSO-MOH)360 000 €2
ItalyFondazione Regionale per la Ricerca Biomedica (FRRB)1 500 000 €3
ItalyMinistero della Salute (MOH-IT)1 000 000 €2-3
LatviaLatvijas Zinatnes Padome (LZP)600 000 €1-2
LithuaniaLietuvos Mokslo Taryba (LMT)300 000 €1-2
MaltaXjenza Malta (XM)500 000 €1-2
MoldovaNational Agency for Research and Development (NARD)100 000 €1
NetherlandsNederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)2 000 000 €5
NorwayThe Research Council of Norway (RCN)1 000 000 €3-4
PolandNarodowe Centrum Nauki (NCN)750 000 €2-3
PortugalFundacao para a Ciencia e a Tecnologia (FCT)400 000 €2-4
SlovakiaCentrum Vedecko Technickych Informacii Slovenskej Republiky (CVTI SR)1 200 000 €2-6
South AfricaSouth African Medical Research Council (SAMRC)250 000 €1-2
SpainInstituto Aragones de Ciencias de la Salud (IACS)150 000 €1-2
SpainAgencia Estatal de Investigación (AEI)1 000 000 €5-6
SpainInstituto de Salud Carlos III (ISCIII)750 000 €2-3
SwedenVetenskapsrådet, Swedish Research Council (SRC)17 000 000 SEK3-5
SwitzerlandSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNSF)1 214 285 CHF3-4
TurkiyeTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)500 000 €3-4
United KingdomMedical Research Council – United Kingdom Research and Innovation (MRC – UKRI), Department of Health and Social Care (DHSC)1 000 000 £6
United KingdomInnovate UK – United Kingdom Research and Innovation (Innovate UK – UKRI), Department of Health and Social Care (DHSC)1 086 000 £3-6

Eligible call topics and One Health settings, and the eligibility of clinical trials (pilots) per funding organisation.

CountryFunding organsiationEligible Topic(s)Eligible One Health settingsEligibility clinical trials (pilots)
AustriaFonds zur Förderung der Wissenschaftlichen Forschung (FWF)1, 3Human Health, Animal Health, Environment, Plant HealthYes, non-commercial clinical trial pilots only
BelgiumBelgium Fonds de la Recherche Scientifique (FNRS)1, 2, 3Human Health, Animal Health, Environment, Plant HealthNo
BelgiumFonds Wetenschappelijk Onderzoek-Vlaanderen (FWO)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
BelgiumService Public de Wallonie (SPW)1Human Health, Animal Health, Environment, Plant HealthNo
CanadaCanadian Institutes of Health Research (CIHR)3Human HealthYes
Czech RepublicMinisterstvo Zdravotnictvi Ceske Republiky (MZCR)/ Agentura pro zdravotnicky vyzkum (AZVCR)1, 2, 3Human HealthYes
DenmarkInnovationsfonden, Innovation Fund Denmark (IFD)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
EstoniaSihtasutus Eesti Teadusagentuur (ETAG)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
FinlandSuomen Akatemia (AKA)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
FranceAgence Nationale de la Recherche (ANR)1, 2, 3Human Health, Animal Health, Environment, Plant HealthNo
GermanyBundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)/ Deutsches Zentrum für Luft- und Raumfahrt Projektträger (DLR-PT)1, 2Human Health, Animal Health, Environment, Plant HealthYes
HungaryNemzeti Kutatási, Fejlesztési Innovációs Hivatal (NKFIH)1, 2Human Health, Animal Health, Environment, Plant HealthYes
IrelandDepartment of Agriculture, Food and the Marine (DAFM)3Animal Health, Environment, Plant HealthNo
IrelandTaighde Éireann – Research Ireland (TÉ-RI)1, 2, 3Human Health, Animal Health, Environment, Plant HealthNo
IrelandThe Health Research Board (HRB)2Human HealthYes
IsraelMinistry Of Health – Chief Scientist Office (CSO-MOH)1, 2, 3Human Health, Animal Health, Environment (A relation to Human Health is required.)Yes
ItalyFondazione Regionale per la Ricerca Biomedica (FRRB)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
ItalyMinistero della Salute (MOH-IT)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
LatviaLatvijas Zinatnes Padome (LZP)1, 2, 3Human Health, Animal Health, Environment, Plant HealthNo
LithuaniaLietuvos Mokslo Taryba (LMT)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
MaltaXjenza Malta (XM)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes (Ethical clearance is a prerequisite for clinical trial approval.)
MoldovaNational Agency for Research and Development (NARD)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
NetherlandsNederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)1, 2, 3
Human Health, Animal Health, Environment, Plant Health
No
NorwayThe Research Council of Norway (RCN)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
PolandNarodowe Centrum Nauki (NCN)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
PortugalFundacao para a Ciencia e a Tecnologia (FCT)1, 2, 3Human Health, Animal Health, Environment, Plant HealthNo
SlovakiaCentrum Vedecko Technickych Informacii Slovenskej Republiky (CVTI SR)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
South AfricaSouth African Medical Research Council (SAMRC)1, 2, 3Human Health, Animal Health, Environment, Plant Health (A relation to Human Health is required.)Yes
SpainInstituto Aragones de Ciencias de la Salud (IACS)1, 2, 3Human Health, Animal Health, EnvironmentNo
SpainAgencia Estatal de Investigación (AEI)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
SpainInstituto de Salud Carlos III (ISCIII)1, 2, 3Human Health, Animal Health, EnvironmentYes
SwedenVetenskapsrådet, Swedish Research Council (SRC)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
SwitzerlandSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNSF)1, 2, 3Human Health, Animal Health, Environment, Plant HealthYes
TurkiyeTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)1, 2, 3Human Health, Animal Health, Environment, Plant HealthNo
United KingdomMedical Research Council – United Kingdom Research and Innovation (MRC – UKRI), Department of Health and Social Care (DHSC)3Human HealthYes
United KingdomInnovate UK – United Kingdom Research and Innovation (Innovate UK – UKRI), Department of Health and Social Care (DHSC)1, 2Human Health, Animal Health, Environment, Plant HealthYes

National rules and requirements

The funding will be provided by the national/regional research funding organisations participating in the call. Each of them will fund their national/regional applicants, according to their own eligibility rules.

To be eligible for funding, applicants must comply with the regulations and scientific remits of their own funding organisations as detailed in the National and Regional Requirements or specific regulations of their corresponding funding partner organisation (see Annex A). Applicants are strongly advised to confirm their funding eligibility with their national/regional funding organisation before submission.


4. General conditions for application

  • The call will only support transnational research and innovation projects. You can find more information on the rules for composing your consortium in the section “Composition of the transnational consortium”.  
  • The call will follow a two-step evaluation process (submission of a pre-proposal; successful consortia will be invited to submit a full proposal). 
  • Pre-proposals and full proposals must be written in English, and must follow the format and the guidelines provided in the pre-/full proposal template. Pre-proposals or full proposals that do not follow the template guidelines (i.e. length of the different sections, number of CVs and letters of intent) will be rejected without further review. The pre-proposal template can be found on the EUP OHAMR website. The full proposal template will be sent to the project coordinators invited to the next evaluation stage. 
  • Pre-proposals and full proposals must be submitted by the project coordinator on the EUP OHAMR on-line submission platform. No other means of submission (i.e. post or e-mail) will be accepted. Please note that some funding organisations might request an additional mandatory submission on their own national/regional platform (see Annex A). Pre-/full proposals submitted on a national/regional platform but not on the EUP OHAMR submission platform will be rejected without further review. 
  • In absence of other information, the call will follow the timeline indicated in the timetable present in the next section. Applicants must respect the submission deadlines indicated. Submission of pre-proposals or full proposals after the submission timeline will not be accepted. Applicants must consider enough time to complete the information on-line. In particular, please consider that collecting some information, such as the Participant Identification Code (PIC) of your research organisation, may require external procedure. Applicants should also ensure that they will have a proper internet connection at the time of submission. 
  • All questions related to the general eligibility rules and general evaluation process should be addressed to the EUP OHAMR Joint Call Secretariat (JCS) (EUPOHAMR_calls@agencerecherche.fr). All questions related to the national/regional eligibility rules and national/regional eligibility costs should be addressed to the national/regional funding organisations indicated in the Annex A.  
  • The only official communication line between the project consortia and the JCS is the project coordinator”. Throughout the application procedure the JCS will only contact by e-mail the project coordinators, who must forward all information to other partners of their consortia. This includes evaluation results. 

Resources


5. Call timeline

  1. Call pre-announcement

    Completed

    October 2025

  2. Publication of the call

    Completed

    18 November 2025 (11:00 CET)

  3. Webinar for applicants

    Completed

    26 November 2025 (14:00 CET)

  4. Deadline pre-proposals

    Completed

    2 February 2026 (13:00 CET)

  5. Communication of the results of the pre-proposal assessment

    Completed

    29 April 2026

  6. Deadline full proposals

    Completed

    17 June 2026 (13:00 CEST)

  7. Final funding recommendation announced to applicants

    Completed

    30 October 2026

  8. Publication of the results on the EUP OHAMR Website during the AMR Awareness Week

    Completed

    16 November 2026

  9. Projects start

    Current stage

    December 2026 – April 2027


6. Composition of the transnational consortium

To be eligible, the submitted pre-/full proposals must respect the following eligibility rules regarding the composition of their consortium. Consortia not respecting the following eligibility rules will be rejected without further review.

For all applications:

  • The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).  
  • The consortium can include a maximum of six (6) project partners (including non-funded partners, Figure 1). The maximum number of partners can be increased to seven (7) if the consortium includes: 
    • at least one partner from an under-represented country or
    • at least one partner where the Principal Investigator meets the definition of an Early-Career Researcher or
    • a start-up, SME, or an Industry.
    • For the purpose of this call, the under-represented countries are Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Moldova, Poland, and Slovakia.
  • A consortium cannot include more than two (2) partners requesting funding from the same funding organisation.  
  • Hungarian legal entities affected by the Council Implementing Decision (EU) 2022/2506 are eligible to apply to calls for proposals as non-funded partners (i.e. without requesting or receiving funding from the Call).  
  • A consortium cannot include, as funded partners as well as non-funded partners, any legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine, or any legal entities established outside Russia but whose proprietary rights are directly or indirectly owned for more than 50% by a legal person, entity or body established in Russia. This list is not extensive and may evolve. Please consult the general annexes of the 2023-2025 Horizon Europe funding programme for more information on other restrictive measures. A principal investigator can coordinate only one (1) submitted pre-proposal/ full proposal. 
  • At both the pre- and full proposal stages, all partners, including non-funded partners, must submit a signed letter of intent along with their pre-/full proposal (the templates to be used for the letters of intent are included in the pre-/full proposal templates). In the absence of these letters, the proposal will be declared ineligible. At the pre-proposal stage, the letter of intent must be signed by the project investigators representing the different partner institutions. At the full proposal stage, the letter of intent should also be signed by a person having the legal mandate to represent the partner institutions. 

Joint research proposals may be submitted by partners belonging to the following categories (according to national/regional regulations; certain categories may not be eligible for funding by a specific funding organisation, or some categories may be mandatory, please see Annex A): 

  • Academia (public and private universities, other higher education institutions or research institutes). 
  • Clinical/public health sector (hospitals/public health and/or other health care settings and health organisations, including primary health care). 
  • Enterprises (private companies of all sizes involved in research and innovation). 
  • Operational stakeholders – e.g. patient advocacy organisations, municipalities and local governments, local/national NGOs. Operational stakeholders should be able to provide useful knowledge to the consortium, ensure the consortium’s research is useful and translatable to their (or other) organizational contexts, and/or influence decision making or create change within their organisations. Operational stakeholders should be engaged in the research process from conception of the study to dissemination. 

Each partner institution will be represented by one Principal Investigator who will be a researcher scientifically responsible for the implementation of tasks assigned. 

To avoid conflicts of interest, employees of the EUP OHAMR beneficiaries are not allowed to apply to this call, with the exception of the staff working in AGES, ISCIII, IACS, TUBITAK and DLR. AGES has been excluded from the call preparation. Firewall measures (such as organisation of the work in separate divisions) have been put in place internally in ISCIII, IACS, TUBITAK and DLR to guarantee an equal treatment of the applicants and applications. In particular, the persons working on the call implementation will ensure that no confidential information will be shared with their research community.

  • Project partners not eligible for funding (e.g. from countries not participating in the call or not fundable according to national/regional regulations of the funding partner organisations) may be involved in projects if they bring their own funding.  
  • The budget of non-funded partners must be included in the proposal (In-Kind Budget) and shall not exceed 30% of the requested total transnational project budget.  
  • The number of non-funded project partners in a consortium must not exceed the number of funded partners.  
  • A project partner not receiving funding cannot be the coordinator of a proposal. 
  • Non-funded partners have the same responsibilities as funded partners, i.e. they must accept all EUP OHAMR rules and guidelines as set out in this Call Text. 

Composition of the consortium should not be modified between the pre- and the full proposal except for widening (see below), in case of force majeure/unforeseen event (e.g. change of professional affiliation, lab relocation, prolonged absence of the Principal Investigator, etc.), or upon recommendation of the Peer Review Panel or request of the Call Steering Group. In any case, changes in the composition of the consortium must be approved by the board of funders organising the call ahead of the submission of the full proposal. In particular, the Principal Investigator representing the coordinating research institution should send an e-mail to the JCS, and to the respective funding organisations, at least 15 calendar days before the full proposal submission deadline to confirm the eligibility of the proposed modifications. 

  • Widening: Consortia which are invited to the second stage of the call (full proposal) will be able to increase their initial size by adding one (1) new partner eligible for funding by an under-subscribed funding organisation. The total number of partners in the consortium must not exceed eight (8). An under-subscribed funding organisation is a funding organisation that may underspend the full amount of funds it has committed to the call. Consortium coordinators will be notified of this option in their invitation letter to submit a full proposal. The list of under-subscribed funding organisations will be included in the full proposal template. The widening process promotes inclusiveness, ensure global participation, relevance and impact of the submitted projects in and outside Europe, as well as maximisation of the use of the committed resources. 

Resources


7. Financial modalities

Funding is initially granted for a maximum of three years in accordance with national/regional regulations and applicable legal provisions. 

Project partners will be funded by their relevant national/regional funding organisation. Therefore, eligible costs, funding rules and the type of studies allowed will vary between the respective funding organisations (see Annex A). Thus, it is recommended that each project partner defines their own budget in accordance with the funding rules of their own country/region. Please note that some funding organisations may limit the number of national/regional applicants per proposal or may limit the maximum budget national/regional applicants can request within a consortium.  

For information on the specific funding rules and eligibility criteria of the national/regional funding organisation: 

  • read Annex A: National rules and requirements carefully 
  • in addition, applicants are strongly advised to reach out to their relevant funding organisation before applying; please note that for some countries/regions it might be mandatory. 

Any budget change between the pre-proposal and the full proposal must be approved by the national/regional funding organisations before submission (provided that: it complies with the national / regional rules, that the oversubscription of the funding organisation does not surpasses the threshold, that the newly requested budget still complies with the eligibility rules regarding the composition of the consortium and that the changes are duly justified and related to the scope and ambition of the proposal). 

Please note

Please note that if a partner is found to be non-eligible at any step of the process by one of the funding organisations, the entire proposal could be rejected without further review.


8. Social and gender equity, cultural sensitivity and economic viability

It is important that consortia and research proposals are founded upon principles of social and gender equity, cultural sensitivity and economic viability. Consortia are highly encouraged to apply these principles to the composition, leadership and management of research projects. Especially where Low- and Middle-income countries are involved in the proposal, the impact to improving health and wellbeing should be considered. 

Where relevant, research projects are expected to apply an intersectional and multi-dimensional approach by integrating sex, gender and other individual and population-level determinants of health (such as age, socio-economic status, ethnicity) into the project’s design, implementation, monitoring, evaluation and knowledge translation activities.  

Research projects are expected to consider individual- and population-level determinants of health when collecting and analysing data to design and/or implement interventions in ways that are accessible and affordable to target beneficiaries, to systematically capture and report on sex, gender, and other relevant factors in the project research outputs, and to meaningfully engage the participation of targeted marginalised groups in the research activities. 


9. Evaluation

The evaluation process will comply with the principles of transparency, equal treatment and non-discrimination.

Formal check and evaluation of pre-proposals 

The JCS will check all proposals to ensure that they meet the call’s formal criteria (i.e. date of submission; number and category of participating countries; inclusion of all necessary information in English; appropriate limits on length; signature of the letters of intent). In parallel, the JCS will forward the proposals to the national/regional funding organisations, which will perform a check for compliance with national/regional regulations. Each proposal passing both eligibility checks will be evaluated independently by three reviewers for a first evaluation (see evaluation criteria below). Potential conflicts of interests of the evaluators will be taken into consideration during the allocation of the proposals. The reviewers will perform the assessment of the pre-proposals and complete a written evaluation form with scores and comments for each evaluation criterion. During a Peer Review Panel (PRP) meeting, the reviewers will discuss all proposals and agree on a consensus score for each proposal. The outcome of the PRP will consist of 3 ranking lists (one ranking list for each topic). To avoid conflicts of interest, evaluators with a conflict related to a specific proposal (i.e. co-publication with one of the applicants during the last 5 years, current collaboration with one of the applicants, same research centre as one of the applicants, personal or professional links with one of the applicants that may compromises the evaluator impartiality, involvement in the preparation of the proposal) will not participate in the discussion of that proposal. The board of funders will meet to decide which proposals will be invited to submit a full proposal based on the reviewers’ recommendations and to ensure a reasonable balance of requested and available national/regional budgets. Pre-proposals which do not pass this assessment will not be invited for the full proposal stage. The consortia will receive a summary review report without scores written by one of the experts in charge of evaluating the proposal. 

Formal check and evaluation of full proposals 

The JCS will check the full proposals to ensure that they meet the call’s formal criteria and have not changed substantially from the respective pre-proposals (e.g. composition of the consortium, the objectives of the project or the requested budget). In parallel, the JCS will forward the proposals to the national/regional funding organisations, which will perform a check for compliance with national/regional regulations. Each full proposal passing both checks will be allocated to three reviewers taking the potential conflicts of interest into consideration. The reviewers will perform the assessment of the full proposal and complete a written evaluation form with scores and comments for each criterion (see evaluation criteria below). During a second PRP meeting, the reviewers will discuss all proposals and produce 3 ranking lists of proposals recommended for funding (one ranking list for each call topic). To avoid conflicts of interest, evaluators with a conflict related to a specific proposal will not participate in the discussion of that proposal. The final summary review report prepared by the evaluators will be sent to the respective project coordinators. 

Ethics and legal requirements 

Please note that at the full proposal stage, applicants will be required to complete a self-assessment checklist for ethics and to provide details on safety, animal studies, genetically modified organisms and microorganisms, environmental hazards and waste handling, data management, statistical methods, ethics and legal issues. Applicants should anticipate this requirement and ensure that they have consulted with relevant experts to verify the feasibility of the project, and that the proposal can be completed within the defined budget and within the prescribed time window. 

Full proposals recommended for funding by the PRP and selected for funding by the board of funders will undergo an ethics review by an Ethics Panel. Ethics experts will remotely check the selected proposal for their compliance with ethical norms and regulations. A meeting will also be organised for a discussion between the various ethics experts. If necessary, the ethics experts may ask the consortium for clarifications. The Ethics experts may highlight some vigilance points that need to be monitored during the implementation of the funded project. Only those proposals approved by both the scientific evaluation and ethics assessment (complying with all central Horizon Europe and regional/national ethical requirements) will be funded. 

Decision 

The funders will take their funding decision, based on the ranking lists established by the PRP, the available funding and the Ethics panel recommendations. The JCS will send by e-mail the funding recommendation to the project coordinator, who is then responsible to communicate this information to the respective project partners. 

Redress Procedure 

Applicants can appeal against the evaluation outcome if they suspect a breach in the implementation of the evaluation and selection procedures. This redress procedure only covers the procedural aspects of the evaluation. 

A mere disagreement with peer reviewers or panel members’ comments are not grounds for an appeal. The redress procedure will not call into question the scientific or technical judgement of appropriately qualified experts. 

The applicants shall submit their appeal against the evaluation outcome to the JCS via e-mail (EUPOHAMR_calls@agencerecherche.fr) up to 7 calendar days after the date of the notification of evaluation outcome sent by the JCS at the end of each step ( evaluation of the pre- or full proposal). 

For an appeal to be admissible the following conditions must be met: 

  • The appeal must be submitted by the project coordinator of the proposal to which the appeal relates 
  • Only one appeal per proposal can be submitted after each step 
  • The appeal must contain the following minimum information: the name of the call for proposals, the proposal acronym, the title of the proposal, a description of the alleged shortcomings of the evaluation procedure. 

The appeal must demonstrate a procedural irregularity, factual or manifest errors in the evaluation process, misuse of powers, or a conflict of interests. Appeals that do not meet the above conditions, or do not deal with the evaluation of a specific proposal or express mere disagreement with the result or the reasoning of the evaluation will be judged as not suitable for redress. 

Upon receipt of an appeal, an acknowledgement of receipt will be sent by the JCS as soon as the e-mail is read. The acknowledgement shall report the redress process and the anticipated date by which a decision on the appeal will be communicated to the appellant. All appeals received by the 7 calendar days deadline will be processed together by a designated redress Committee and the decision will be communicated to the appellant within 14 calendar days from the deadline for submitting the appeals. 

Questions related to the national/regional eligibility decisions will not be handled by the JCS and need to be addressed to the respective national/regional funding organisation (see Annex A).

1. Excellence  

  • Clarity and pertinence of the objectives (pre-proposal and full proposal) 
  • Credibility of the proposed approach and methodology, in relation to the research objectives (pre-proposal and full proposal) 
  • Soundness and research base of the concept (pre-proposal and full proposal) 
  • Novelty, potential to advance the field, timeliness, and innovation (pre-proposal and full proposal) 
  • Scientific excellence of the consortium (pre-proposal and full proposal) 

2. Impact 

  • Impact of the proposal to achieve the objectives of the call topic (pre-proposal and full proposal) 
  • Potential of the expected results for clinical, public health, and animal health, agriculture, or environmental benefit (including economic viability/sustainability where appropriate) (pre-proposal and full proposal) 
  • Relevance and consideration of the One Health concept (pre-proposal and full proposal) 
  • Potential for fostering a longer-term international network of researchers. For example, bringing together specific know-how and/or innovative technologies, gathering a critical mass of patients or biological material, sharing of resources (models, databases, biobanks, etc.), and international comparisons (pre-proposal and full proposal) 
  • Potential reach of the project results, including dissemination and communication measures. Accessibility of the proposed innovative strategy (different geographical areas, different populations including low-resource or underserved populations) (full proposal only) 
  • Appropriateness of end-user and stakeholder participation/engagement, for example, policy makers, industry, patient organisation, health and veterinary care, farmers, etc. (full proposal only) 

3. Quality and efficiency of the implementation 

  • Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks within the given timeframe (pre-proposal and full proposal) 
  • Adequate distribution of the tasks between the project partners considering the required expertise (pre-proposal and full proposal) 
  • Strength of the transnational collaboration (balanced geographical distribution of the tasks) (pre-proposal and full proposal) 
  • Integration of social, economic, equity and cultural dimensions into the proposed research (pre-proposal and full proposal) 
  • Quality of the proposed Open Science practices, data management, Intellectual Property management, and Freedom to Operate where appropriate (full proposal only)) 
  • Appropriateness of the management and governance structures and procedures, including risk and innovation management (full proposal only) 
  • Potential exploitation (including strategy to identify and address potential barriers) and relevance of the outcomes of the findings beyond the current project. (long term strategy) (full proposal only) 
  • Contingency plan, including risk assessment and mitigation (including of unforeseen circumstances like Covid-19) (full proposal only) 
  • Justification of the requested budget and cost-effectiveness of the project (appropriate distribution of resources in relation to project’s activities, partner responsibilities and time frame) (full proposal only) 

Proposals not relevant to the call topics and objectives (out of the scope) will not be funded, independently of their scientific quality. The decision if a project is in/out of scope will be taken by the reviewers and evaluation panel in the pre-proposal stage. 

Evaluation scores will be awarded for the three main criteria (Excellence, Impact and Implementation), and not singularly for the different aspects listed below the criteria, although these different aspects will be taken into consideration in scoring the main criteria.  

The weight of each of the three main criteria (Excellence, Impact and Implementation) is equal. 

0: Failure. The proposal fails to address the criterion in question or cannot be judged because of missing or incomplete information. 

1: Poor. The proposal shows serious weaknesses in relation to the criterion in question. 

2: Fair. The proposal generally addresses the criterion, but there are significant weaknesses that need corrections. 

3: Good. The proposal addresses the criterion in question well, but few improvements are possible. 

4: Very good. The proposal addresses the criterion very well, but minor improvements are possible. 

5: Excellent. The proposal successfully addresses all aspects of the criterion in question, there are no suggestions for improvement. 

In order for an application to be considered fundable, the threshold score for individual criteria is set at three (3) (of a maximum of five (5)). The overall threshold for the score for all three criteria together is set at ten (10). The maximum score that can be reached from all three criteria together is fifteen (15) points.


Annex A: National rules and requirements

The funding will be provided by the national/regional research funding organisations participating in the call. Each of them will fund their national/regional applicants, according to their own eligibility rules.

To be eligible for funding, applicants must comply with the regulations and scientific remits of their own funding organisations as detailed in the national and regional requirements or specific regulations of their corresponding funding partner organisation, see link below.

Applicants are strongly advised to confirm their funding eligibility with their national/regional funding organisation before submission.

National rules and requirements

National Rules and Requirements

Annex B: Responsibilities of the Grantees

This section outlines the terms and conditions associated with your grant, including consortium agreements, Open Science requirements, reporting obligations, ethical considerations, and communication and dissemination activities. As an applicant you must take these requirements into account while drafting your budget and planning your project resources and workload.

Partners from the projects approved for funding will subsequently enter into granting arrangements with the relevant funding organisations, according to their applicable grant awarding process and will be funded directly by the respective Funding organisations. Partners from the projects approved for funding must fix a common scientific project start date, which will be the reference date for the progress reports. Projects are expected to start between December 2026 and April 2027.

The ultimate goal of the EUP OHAMR is to bring together national research efforts in order to make better use of public Research and Development (R&D) resources and to tackle common global challenges more effectively in selected key areas.  

For EUP OHAMR activities to contribute effectively to socioeconomic progress, the results of the research activities must be exploited. This requires appropriate identification and protection of the intellectual property being generated and effective knowledge transfer. Any particular protection and exploitation strategy should be agreed before the research activities start. The ten principles of Socially Responsible Licensing should be part of this strategy. 

Depending on the nature of the research and on the interests of the different parties, if there are opportunities for exploitation, it is recommended that parties decide in advance on either adopting a common exploitation strategy or leaving exploitation of results to the party best placed to commercialise it, with appropriate compensation mechanisms for the contributing parties. Please see section below for a link to a simplified consortium agreement template, available on the DESCA website. National rules and regulations may apply, please consult Annex A. 

The partners of each funded project are required to set up and sign a Project Consortium Agreement (PCA) in order to deal with issues related to the role, tasks and responsibilities within the consortium, the protection of intellectual property, and where applicable how the consortium will address the ten principles of Socially Responsible Licensing. The coordinator is responsible for providing the PCA signed by all partners to the EUP OHAMR secretariat (reporting@ohamr.eu) when requested during the mid-term progress reporting. Upon request, this consortium agreement must be made available to the concerned funding organisations. The project consortium is strongly encouraged to sign the PCA before the official project start date and, in any case, the PCA should be signed no later than six months after the scientific project start date. The PCA needs to be in accordance with the national funding rules of the respective funding partner organisations – see Annex A. Please note that certain funding organisations may need the signed PCA to release the funds.  

The PCA must address (as a minimum), the following points: 

  • common start date and duration of the research project and the duration of the PCA; 
  • organisation and management of the project; 
  • role, tasks, and responsibilities of each partner; 
  • the resources and funding; 
  • confidentiality and publishing; 
  • Intellectual Property Rights (if applicable); 
  • how the ten principles of Socially Responsible Licensing will be addressed (if applicable); 
  • decision making within the consortium; 
  • handling of internal disputes; 
  • the liabilities of the research partners towards one another (including the handling of default of contract). 

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the PCA.  

Please see the DESCA website for further information and templates of a simplified consortium agreement under the Horizon Europe Framework.

EUP OHAMR requires grant holders to make data and research findings resulting from their project available following the principle “as open as possible, as closed as necessary”. To this end, EUP OHAMR supports research consortia in implementing Open Science practices, focusing on data management according to FAIR principles (Findable, Accessible, Interoperable, Re-usable), and sharing research findings via open access publications. The open science requirements for EUP OHAMR funded projects are in line with the guidelines for research data management of Horizon Europe. 

Data Management  

Data management is mandatory for EUP OHAMR funded projects. It involves first that applicants are strongly encouraged to look for options for re-using existing data, standards, tools, and infrastructures, particularly those familiar to the AMR research community, to enhance interoperability.  

Secondly, applicants must ensure that they plan the appropriate activities for their project, enabling them to make data available as soon as possible and re-usable for verifying results, and future research and innovation. Their plan must include the necessary expertise on data stewardship5 and sufficient budget to be able to manage research data, in line with the FAIR principles. Grant holders will receive more details on the requirements later in the process.  

Note that all requirements and guidelines referring to ‘data’, also apply to other resources that are used to perform the research, and are needed to re-use or validate the data and published research findings. These resources include for instance physical research outputs (such as biological samples, molecular derivatives), research software, (meta)data standards and tools. 

Capacity and community building

The EUP OHAMR plans to organize online-awareness and -training workshops for granted projects. These activities will be organized throughout the course of the partnership. Attendance (on-line) to the workshops will be mandatory for the coordinators and partners of the funded projects (FAIR awareness) and for the project’s data stewards and/or other members of the project group who are involved in data-related tasks (data FAIRification).  

The aim is to improve knowledge and skills in creating re-usable and machine-actionable (i.e. FAIR) data, and to build an OHAMR-community of data-experts. Funded projects benefit from the workshops as they lead to a common understanding on data FAIRification and its benefits in research, an equal playing field for researchers, and preventing the reinvention of the wheel by individual research groups. 

The EUP OHAMR as a whole benefits as the workshops facilitate the research community to benefit optimally from reusable data and emerging AI-approaches to advance knowledge generation on OHAMR. 

What needs to be done in the application phase? 

Applicants must check the requirements for data management and data sharing of the relevant national funder. EUP-OHAMR specific requirements will be provided later in the process, when grants are awarded. 

Applicants do not need to deliver a data management plan (DMP) yet. However, already in this phase, they must plan carefully what is needed for re-using existing data (including the permission required therefore), and for managing data (and other resources) to become findable and re-usable for future users. The application must particularly include: 

  • A plan to involve experts on data stewardship, who are facilitated to dedicate their expertise to the project to realise data re-usability. The data-experts must also be able to participate in workshops aimed at building FAIR data-expertise and community engagement. 
  • Sufficient budget to enable the data-experts to be involved in the project. 

What needs to be done once the project is funded? 

Once the project is funded, a DMP must be developed. The Project Coordinator must prepare a DMP no later than six months after the scientific project start date. The project coordinator is responsible for sending an updated DMP with the midterm and the final term progress reports of the project to the EUP OHAMR secretariat (reporting@ohamr.eu). The Horizon Europe template for DMP should be used. Grant holders will receive further information, when grants are awarded. 

Finalising data management: At the end of the project, research data and other outputs, software and other tools or instruments necessary to validate the publications’ conclusions must be made available by depositing in a trusted repository. 

The final DMP must be completed and delivered, including information on how resources can be found, where they are stored, and access conditions. 

Open Access Publications 

Beneficiaries must disseminate results, including scientific publications, to the public as soon as possible. Peer-reviewed scientific publications must be made available in open access. Guidelines and options to comply to the requirements are available on How to comply with Horizon Europe mandate for publications.  

Peer-reviewed publications issued from EUP OHAMR funded projects must be open access by depositing the final version or peer-reviewed manuscripts in a trusted repository. For journal articles, a Creative Commons Attribution (CC BY) or equivalent open license should be requested to the editor. For publishing long-texts, Creative Commons Attribution Non-Commercial/Non-Derivatives licenses are also allowed. In addition, the research outputs, tools, or instruments necessary to validate the publications’ conclusions should be deposited in a trusted repository.  

Each participant may also be required to comply with the Open Access policy of its funding organisation (See country-specific information in Annex A). To find out if a scientific journal complies with open access, check on the Directory of Open Access Journals or the Journal Checker tool. All research projects funded by EUP OHAMR are eligible to publish on Open Research Europe (ORE), the Platform of the EC at no cost. 

Overall project monitoring will be the responsibility of the EUP OHAMR Secretariat (reporting@ohamr.eu). On behalf of the project consortium, the coordinator is required to submit progress reports (mid-term and final-term) as to be outlined in the monitoring policy of the transnational projects supported under the EUP OHAMR. 

The monitoring outputs and outcomes from the reports will be collected and made accessible to all funding organisations. In addition, the monitoring of each funded project will also be done through follow-up meetings with expert panel to assess the outcomes and impact of projects. The EUP OHAMR Secretariat will contact the coordinator requesting the reports as per required timeline and will provide to provide detailed information on the reporting needs. 

Other than the progress reports, grantees have an obligation to provide the EUP OHAMR with updated information of the consortium and its results, if requested, even beyond the tenure of the projects.

Each funded consortium must have all necessary ethics approvals for research on animals, and/or research involving human subjects or data/samples obtained from human subjects according to national/regional law and regulation and in compliance with EU Horizon Europe rules before initiation of such research. Applications for ethics approval and ethics approvals should be made available immediately to the EUP OHAMR Secretariat upon request. The EUP OHAMR may perform an ethics review of the research at any time (evaluation and/or follow-up of the funded projects).  

Project coordinators must inform the EUP OHAMR Secretariat as well as the funders supporting the project if ethics approvals are denied. The notification should be communicated no more than 14 calendar days after the rejection and the proposed rescue plan (new request for ethics approval, modification of the workplan/ project scope) must be approved by the funders supporting the project. 

Any partner of a consortium in breach of research ethics regulations will subject the whole project for re-evaluation by all funding organisations of the project resulting in potential inhibition of all activities, withdrawal of funds, cancelling of contracts, and /or legal action or other sanctions according to national law. 

The funded projects may need to request changes in the project consortium (for e.g. change of organisation, change of coordinator/partner) or in the project workplan due to circumstances beyond their control that might prevent them from conducting research and thereby hinder implementation of their project during its tenure. These changes should be exceptional and supported by reasonings due to scientific or administrative constraints. Substantial changes must be approved by the different funding organisations involved in the project. The project coordinator should inform the EUP OHAMR Secretariat (postaward@ohamr.eu) as soon as possible using the project change request form. The EUP OHAMR Secretariat will inform the relevant funding organisations, who will decide upon the proper action to be taken.

Coordinators of the funded projects are required to deliver, upon request, an abstract or a short video presenting their project or a summary of their project results suitable for communication and dissemination purposes.  

The project coordinators should be available to participate in meetings/workshops/podcast with the aim of: 

  • disseminating project results; 
  • developing a joint strategy to coordinate and facilitate integration of the planned activities of the EUP OHAMR; 
  • supporting the uptake of the research results by stakeholders;  
  • communicating results across EUP OHAMR. 

Importantly, all funding recipients must ensure that all research outcomes (i.e. publications, tools, software, databases) of transnational EUP OHAMR funded projects include proper acknowledgement of the EUP OHAMR and the respective funding partner organisations using the text below: 

“This project received funding from [name of funding organisations, or an acknowledgment as requested by your national/regional funding organisations] under the umbrella of the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) (GA N° 101217154 of the EU Horizon Europe Research and Innovation Programme).” 

For any oral presentation, the EUP OHAMR logo, the logo of the national/regional funders as well as the EU emblem “co-funded by the European Union” should be displayed (with the same size for each logo). 


Other information

By submitting an application, the applicants consent to the use, processing and retention of their personal data in accordance with article 6.1 (e) and (c) of the General Data Protection Regulation (GDPR) (2016/679) and for the purposes of:  

  • processing and evaluating the pre- and full proposal where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller; 
  • administering any subsequent funding award; 
  • managing the relationship between the applicant and the Funding Partner Organisations; 
  • analysing and evaluating the call; 
  • providing aggregate data to national and European surveys and analyses on the funded projects; 
  • complying with audits that may be initiated by the Funding Partner Organisations and the European Commission (or its agencies). 

In addition, by submitting an application (pre- and full proposal) to this call, the applicants agree to share their personal data with Funding Partner Organizations based outside the European Economic Area and with third parties such as evaluators (some of which may be based outside the European Economic Area) in relation to the above activities. 

The following Funding organisations outside the European Economic Area will use their national data protection rules: 

  • Canada (CIHR) 
  • Israel (CSO-MOH)  
  • Moldova (ANCD) 
  • South Africa (SAMRC) 
  • Switzerland (SNSF) 
  • Turkey (TUBITAK)  
  • the United Kingdom (UKRI)  

By the time of the call launch, the European Commission issued adequacy decisions for personal data protection laws in Israel, Switzerland and the United Kingdom. 

Funding Organizations and third parties may link the data that applicants provide in the application with national, bibliographic or external research funding data which is available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other national/open datasets.

The content of the pre-proposals and full proposals received under this Joint Call is deemed to be confidential, except for consortia including project partners applying for funding from the Swedish funding organisation (SRC). For those consortia, the applications (pre- and full proposals) may be made available upon request after the respective call deadlines.  

Responding to a EUP OHAMR call for proposals, both as project coordinator or project partner, gives the EUP OHAMR, the European Commission and the Funding Partner Organisations the right to use and store the information submitted for analysis of the call success rate, national response rate, etc. 

The proposals will be handled confidentially by the JCS and by the national/regional funding organisations. In selecting the international experts for the PRP, the JCS shall endeavour to avoid any possible conflicts of interest. Each expert will sign a declaration of confidentiality and confirm the absence of conflicts of interest. In case of a conflict of interest the reviewer will be withdrawn from evaluating the respective proposal. Conflicts of interest are managed and recorded throughout the evaluation process. 

Accepting a EUP OHAMR grant award and associated grant contract from a national funding organisation gives the EUP OHAMR, the European Commission and Funding Partner Organisations the right to store, share, and analyse information on beneficiaries and consortia (rules may differ between different countries). Composition of the awarded consortia (Principal investigators, Institution) as well as the title, acronym and abstract of funded projects will be published and openly accessible. No data will be shared with third parties or commercial entities without the formal consent of the project coordinators, except for consortia including project partners applying for funding from the Swedish Funder (SRC). For those consortia, the applications (pre- and full proposals) may be made available upon request after the respective call deadlines. 


Contact

All questions related to the general eligibility rules and general evaluation process should be addressed to the EUP OHAMR Joint Call Secretariat (JCS), which is hosted by the French National Research Agency (ANR).

All questions related to the national/regional eligibility rules and national/regional eligibility costs should be addressed to the national/regional funding organisations.

The only official communication line between the project consortia and the JCS is the project coordinator. Throughout the application procedure the JCS will only contact by e-mail the project coordinators, who must forward all information to other partners of their consortia. This includes evaluation results.

EUP OHAMR Joint Call Secretariat

Yue Xiao and Sophie Gay, French National Research Agency

+33 1 73 54 82 41/ +33 1 78 09 80 39


History of change

Any changes to the call text after 18 November 2025 will be noted here.

2026-01-14, Pre-proposal form updated as follows:

  • Letter of Intent template (p. 11-12): References to “Annex B of the Call text” has been replaced with “the Responsibilities of the Grantees awarded in the JTC1 framework, as described in the call text”
  • Letter of Intent template (p. 11-12): References to “Section 11 of the Call text” has been replaced with “the section of the Call text referring to the General Data Protection Regulation (GDPR)”